Tag Archives: priority review voucher

Cashing in On Duchenne Approval, Sarepta Sells Voucher to Gilead For $125M

Sarepta Therapeutics didn’t just get its first drug to market when the FDA approved the Duchenne muscular dystrophy drug eteplirsen (Exondys 51) last year—it got a potentially lucrative voucher from the FDA too. Today the Cambridge, MA, company cashed that in. Sarepta (NASDAQ: SRPT) this morning sold what’s known as a priority review voucher to […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, New York blog main, San Francisco blog main | Tagged , , , , , , , , , , , , , , , , , , , , | Comments Off on Cashing in On Duchenne Approval, Sarepta Sells Voucher to Gilead For $125M

East Coast Biotech Roundup: X4, Rgenix, Alnylam, Intellia & More

What summer doldrums? It’s still not even Labor Day, yet the deals are already coming fast and furious. So fire up the grill and read on for some Series A rounds, crossover investments, data readouts, option-to-buy deals and more. —As Xconomy reported this week, a stealthy Cambridge, MA-based startup called X4 Pharmaceuticals raised a $37.5 […]

Posted in Boston, Boston blog main, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Biotech Roundup: X4, Rgenix, Alnylam, Intellia & More

With $229M Deal, Amicus Gets a New Drug And Perhaps a Voucher

Just how far has Amicus Therapeutics come in two years? In 2013, the Cranbury, NJ-based company was reeling from a trial failure and restructuring to conserve cash. Now, it’s eyeing its first drug approval and buying a startup in a nine-figure deal. Amicus (NASDAQ: FOLD) this morning is announcing the acquisition of Durham, NC-based Scioderm. […]

Posted in Boston blog main, National blog main, National top stories, New York, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on With $229M Deal, Amicus Gets a New Drug And Perhaps a Voucher

East Coast Biotech Roundup: StartUp Health, Constellation, Highline & More

Nothing like a little drama to end your summer, right? Market volatility dragged biotech down this week, and then lifted it back up—at least as of Friday morning. But if you’re confused by the tumult and looking for some distractions, we’ve got plenty of them below. Read on for details of some biotech and digital […]

Posted in Boston blog main, Boston top stories, National blog main, New York, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Biotech Roundup: StartUp Health, Constellation, Highline & More

East Coast Biotech Roundup: Seres, Editas, PureTech, Pronutria & More

Call it the calm before the storm. All eyes in biotech this weekend will turn to the year’s big cancer meeting, the American Society of Clinical Oncology’s annual bash in Chicago. There’ll be plenty of data to parse through over the next few days, as cancer immunotherapy once again takes center stage and hordes of […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Biotech Roundup: Seres, Editas, PureTech, Pronutria & More

With Asklepion Deal, Retrophin Gets a New Drug—And a Voucher

It was a rough 2014 for Retrophin, which was busy moving on from its former CEO’s ouster. But things brightened up a bit this morning, as the company not only added a new drug to the fold, but also get ahold of an asset that’s been making waves in biotech over the past year—a so-called […]

Posted in National blog main, New York, New York blog main, New York top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , | Comments Off on With Asklepion Deal, Retrophin Gets a New Drug—And a Voucher

East Coast Biotech Roundup: Yumanity, Biogen, Blizzards, & More

Funny thing happened on the East Coast this week. The so-called Blizzard of 2015 threw us New Yorkers into a panic before unexpectedly veering eastward in a post-Christmas miracle and giving the city little more than a dusting. We weren’t relieved; we were livid—at weathermen for scaring us, politicians for shutting the city down for […]

Posted in Boston, Boston blog main, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Biotech Roundup: Yumanity, Biogen, Blizzards, & More

With Gilead’s $125M Purchase, FDA Voucher Program Gains Momentum

[UPDATED 11/19/14, 6:44pm. See below.] The next time Gilead Sciences (NASDAQ: GILD) has a drug ready for an all-important Food and Drug Administration review, it can jump the line. That’s because Gilead, the Foster City, CA-based maker of blockbuster drugs to treat HIV and Hepatitis C, paid a little-known Canadian drug company $125 million for […]

Posted in National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on With Gilead’s $125M Purchase, FDA Voucher Program Gains Momentum

An Intriguing Program Takes on Tropical Diseases—But Not Ebola

[Updated and corrected 9/10/14, 10:05 am. See below.] On August 28, Anthony Fauci, the U.S. National Institutes of Health’s top infectious disease specialist, announced a major trial in concert with GlaxoSmithKline (NYSE: GSK) to test new Ebola vaccines in humans. Fauci called it an “all-hands-on-deck response” to the growing global health emergency in which more […]

Posted in Boston blog main, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | 2 Comments